NCT04994626 2021-08-06Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior TherapiesChineseAMSPhase 2 Unknown20 enrolled